Equities research analysts predict that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Adamis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.15). The company is scheduled to report its next earnings results on Thursday, March 29th.

According to Zacks, analysts expect that Adamis Pharmaceuticals will report full-year earnings of ($0.79) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.78). For the next year, analysts expect that the business will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.67) to ($0.60). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Adamis Pharmaceuticals.

A number of brokerages recently issued reports on ADMP. B. Riley set a $10.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 15th. Maxim Group set a $14.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. Zacks Investment Research lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Finally, ValuEngine lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Adamis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $10.33.

Shares of Adamis Pharmaceuticals (NASDAQ ADMP) opened at $3.60 on Wednesday. Adamis Pharmaceuticals has a 1 year low of $3.20 and a 1 year high of $6.45. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06.

A number of institutional investors have recently made changes to their positions in ADMP. Northern Trust Corp grew its stake in Adamis Pharmaceuticals by 5.5% in the second quarter. Northern Trust Corp now owns 51,108 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 2,686 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Adamis Pharmaceuticals by 131.0% in the third quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 15,577 shares in the last quarter. Virtu KCG Holdings LLC grew its stake in Adamis Pharmaceuticals by 103.2% in the second quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock valued at $200,000 after purchasing an additional 19,538 shares in the last quarter. Wells Fargo & Company MN grew its stake in Adamis Pharmaceuticals by 1,050.3% in the fourth quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after purchasing an additional 25,732 shares in the last quarter. Finally, Advisor Group Inc. grew its stake in Adamis Pharmaceuticals by 149.9% in the third quarter. Advisor Group Inc. now owns 56,001 shares of the specialty pharmaceutical company’s stock valued at $292,000 after purchasing an additional 33,591 shares in the last quarter. 16.54% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Adamis Pharmaceuticals Corp (ADMP) Expected to Post Earnings of -$0.15 Per Share” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/14/adamis-pharmaceuticals-corp-admp-expected-to-post-earnings-of-0-15-per-share.html.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.